The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC).
 
Bhavana Konda
No Relationships to Disclose
 
Michael V. Knopp
No Relationships to Disclose
 
Peter R. Martin
No Relationships to Disclose
 
Susan Geyer
No Relationships to Disclose
 
Maria E. Cabanillas
Consulting or Advisory Role - Loxo
Research Funding - Eisai (Inst); Genentech (Inst); Korea Institute of Science and Technology (Inst)
 
Jonas A. De Souza
No Relationships to Disclose
 
Lori J. Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck
Research Funding - AstraZeneca (Inst); Bayer (Inst); Eisai (Inst)
 
Michael E. Menefee
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Celgene; Genentech; Lilly; Pfizer
Research Funding - Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Loxo
Research Funding - Bristol-Myers Squibb; Eisai; Merck